Drilldown: Medicines - Pharmacopedia

Nav

Choose a table:

Medicines (732)

Medicines > bioavailability

: 100% (IV)

or ~100% (oral)'"`UNIQ--ref-0000001C-QINU`"'

& pregnancy: Limited data

Use the filters below to narrow your results.

None (2)

Kisunla (1) · Leqembi (1)

Anti-amyloid beta (Aβ) monoclonal antibody (2) · targets protofibrils (1) · targets pyroglutamated Aβ in plaques (1)

None (2)

Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)

10 mg/kg IV every 2 weeks (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1)

200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 350 mg/20 mL vial for IV infusion (1)

10 mg/kg q2w (1) · 1400 mg q4w (1)

IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (1)

Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)

Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1)

~12.1 days (1) · ~5-7 days (1)

Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1)

Error in "where" parameter: the string "--" cannot be used within #cargo_query.

There are no results for this report.

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"